R M Ruggeri1, T M Vicchio2, S Giovinazzo2, R Certo2, A Alibrandi3, F Trimarchi2, S Benvenga2, M Trovato2,4. 1. Department of Clinical and Experimental Medicine, Endocrine Unit, University of Messina, Padiglione H, 4 Piano, AOU Policlinico Universitario "G. Martino", via Consolare Valeria, 1, 98125, Messina, Italy. rmruggeri@unime.it. 2. Department of Clinical and Experimental Medicine, Endocrine Unit, University of Messina, Padiglione H, 4 Piano, AOU Policlinico Universitario "G. Martino", via Consolare Valeria, 1, 98125, Messina, Italy. 3. Department of Statistical Sciences (SEFISAST), University of Messina, Messina, Italy. 4. Department of Human Pathology, University of Messina, Messina, Italy.
Abstract
PURPOSE: p53, which is encoded by the tumor suppressor gene TP53, plays a crucial role in the regulation of mechanisms of cell cycle arrest and apoptosis. Some SNPs of TP53, involving a different apoptotic ability of p53, have been associated with increased susceptibility to develop autoimmune diseases as well as cancer. We investigated the genotypic distribution of TP53 exon 4 SNPs in a cohort of Caucasian patients affected by Hashimoto's thyroiditis (HT). METHODS: Peripheral blood for DNA extraction was collected from 109 Caucasian unrelated subjects, 79 HT patients and 30 healthy controls. SNPs analysis was carried out by amplification and sequencing of exon 4 TP53. RESULTS: For the Pro72Arg (rs 1042522) SNP we found these rates in HT patients: 11.4% wild-type C/C (Pro72Pro), 24.0% heterozygous G/C (Pro72Arg), 64.6% homozygous G/G (Arg72Arg). The corresponding rates in healthy controls were 10, 46.7 and 43.3%, respectively. Thus, significantly different were G/C heterozygosity (24.0 vs 46.7 %, p = 0.039) and G/G homozygosity (64.6 vs 43.3%, p = 0.042). These differences were also confirmed when comparing our study population to published Caucasian control groups. The other described SNPs (Pro34Pro rs 11575998, Pro36Pro rs1800370, Pro47Ser rs1800371, and Arg110Leu rs 11540654) were absent or very rare in our study population. CONCLUSIONS: Our preliminary data, the first on a Caucasian population, indicate an increased prevalence of the homozygous genotype Arg/Arg and a decreased prevalence of heterozygous genotype Arg/Pro of rs 1042522 in HT patients compared to controls, suggesting that such SNP may contribute to confer susceptibility to HT.
PURPOSE:p53, which is encoded by the tumor suppressor gene TP53, plays a crucial role in the regulation of mechanisms of cell cycle arrest and apoptosis. Some SNPs of TP53, involving a different apoptotic ability of p53, have been associated with increased susceptibility to develop autoimmune diseases as well as cancer. We investigated the genotypic distribution of TP53 exon 4 SNPs in a cohort of Caucasian patients affected by Hashimoto's thyroiditis (HT). METHODS: Peripheral blood for DNA extraction was collected from 109 Caucasian unrelated subjects, 79 HTpatients and 30 healthy controls. SNPs analysis was carried out by amplification and sequencing of exon 4 TP53. RESULTS: For the Pro72Arg (rs 1042522) SNP we found these rates in HTpatients: 11.4% wild-type C/C (Pro72Pro), 24.0% heterozygous G/C (Pro72Arg), 64.6% homozygous G/G (Arg72Arg). The corresponding rates in healthy controls were 10, 46.7 and 43.3%, respectively. Thus, significantly different were G/C heterozygosity (24.0 vs 46.7 %, p = 0.039) and G/G homozygosity (64.6 vs 43.3%, p = 0.042). These differences were also confirmed when comparing our study population to published Caucasian control groups. The other described SNPs (Pro34Pro rs 11575998, Pro36Pro rs1800370, Pro47Ser rs1800371, and Arg110Leu rs 11540654) were absent or very rare in our study population. CONCLUSIONS: Our preliminary data, the first on a Caucasian population, indicate an increased prevalence of the homozygous genotype Arg/Arg and a decreased prevalence of heterozygous genotype Arg/Pro of rs 1042522 in HTpatients compared to controls, suggesting that such SNP may contribute to confer susceptibility to HT.
Entities:
Keywords:
Hashimoto’s thyroiditis; Single nucleotide polymorphism (SNP); p53; p53 mutations
Authors: Yuji Yamanishi; David L Boyle; Michael J Pinkoski; Artin Mahboubi; Tesu Lin; Zuoning Han; Nathan J Zvaifler; Douglas R Green; Gary S Firestein Journal: Am J Pathol Date: 2002-01 Impact factor: 4.307
Authors: Shuzhong Zhang; Mingquan Zheng; Ryoko Kibe; Yunping Huang; Luis Marrero; Samantha Warren; Arthur W Zieske; Tomoo Iwakuma; Jay K Kolls; Yan Cui Journal: FASEB J Date: 2011-04-06 Impact factor: 5.191
Authors: Marsha Pellegrino; Gianandrea Traversi; Andrea Arena; Marco Cappa; M Manuela Rosado; Marco Andreani; Domenico V Delfino; Fabiola Moretti; Alessandra Fierabracci Journal: PLoS One Date: 2020-01-29 Impact factor: 3.240